Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Patterson-UTI Energy, Inc.
PTEN·Energy
C ★★Sell
Current$13.32
Oct 31, 2026

Patterson-UTI offers cyclical upside from higher rig utilization, stronger completion pricing and Ulterra growth, but weak capital returns, heavy reinvestment needs and a substantial share-price recovery limit its risk-adjusted appeal.

Score
57
NOV Inc.
NOV·Energy
C ★★Sell
Current$19.36
Oct 30, 2026

NOV's specialized oilfield equipment franchise and substantial backlog support a cyclical earnings recovery, but weak cash conversion, low ROIC, and exposure to volatile energy investment undermine its near-term investment appeal.

Score
57
American Airlines Group Inc.
AAL·Industrials
C ★★Sell
Current$12.11
Oct 25, 2026

American Airlines could benefit from premium travel growth and a cyclical fuel-cost recovery, but substantial leverage and weak free cash flow leave its earnings highly vulnerable to prolonged operating pressure.

Score
57
Cleveland-Cliffs Inc.
CLF·Materials
C ★★Sell
Current$14.03
Oct 22, 2026

Cleveland-Cliffs offers significant upside leverage to recovering U.S. steel prices and contract margins, but elevated debt, historically weak free cash flow, and cyclical operating risk undermine the durability of its investment case.

Score
57
ABIVAX Société Anonyme
ABVX·Healthcare
D ★Strong Sell
Current$91.06
Sep 27, 2026

Abivax's Phase 3-validated obefazimod and long cash runway create a credible UC launch path, but its pre-revenue valuation, binary FDA risk, and heavy dilution leave little margin for execution error.

Score
57
Spire Inc.
SR·Utilities
C ★★Sell
Current$85.63
Nov 20, 2026

Spire offers a durable regulated natural gas franchise and attractive dividend income, but elevated leverage, persistent negative free cash flow, and uncertain regulatory earnings recovery constrain investment appeal.

Score
56
Roivant Sciences Ltd.
ROIV·Healthcare
C ★★Sell
Current$41.85
Nov 12, 2026

Roivant offers substantial long-term growth potential through LISRAYA commercialization and a diversified autoimmune pipeline, but its elevated valuation, continuing operating losses, and clinical execution risks limit near-term investment appeal.

Score
56
Lineage, Inc.
LINE·Real Estate
C ★★Sell
Current$35.40
Nov 12, 2026

Lineage owns the world's largest cold-storage warehouse network and offers attractive dividend income, but high leverage, weakening margins, and declining cash generation threaten its recovery.

Score
56
Celldex Therapeutics, Inc.
CLDX·Healthcare
C ★★Sell
Current$31.40
Nov 10, 2026

Celldex's successful pivotal barzolvolimab trials create a credible path toward a differentiated immunology franchise, but absent commercial revenue, continued cash burn, and uncertain launch economics constrain its risk-adjusted investment appeal.

Score
56
Delek Logistics Partners, LP
DKL·Energy
C ★★Sell
Current$51.77
Nov 9, 2026

Delek Logistics offers high cash income and identifiable midstream growth opportunities, but its premium enterprise valuation, substantial leverage, and narrowing distribution coverage weaken the investment case.

Score
56
Kimberly-Clark Corporation
KMB·Consumer Staples
C ★★Sell
Current$108.43
Nov 8, 2026

Kimberly-Clark's iconic consumer brands and Kenvue acquisition offer major synergy potential, but substantial share dilution, higher debt, and integration costs threaten near-term per-share value creation.

Score
56